Immix Biopharma IncNASDAQ:IMMX
- LAST PRICE2.0300
- TODAY'S CHANGE (%)-0.0300 (-1.4563%)
- Bid / Lots2.0100/ 1
- Ask / Lots2.1800/ 2
- Open / Previous Close2.0100 / 2.0600
- Day Range
- 52 Week Range
- Volume73,189
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IMMX |
|---|---|---|
| 09:32 ET | 1172 | 2.01 |
| 09:38 ET | 600 | 2.05 |
| 09:48 ET | 5997 | 2.0601 |
| 10:01 ET | 2680 | 2.09 |
| 10:06 ET | 1000 | 2.0999 |
| 10:14 ET | 230 | 2.08 |
| 10:26 ET | 1250 | 2.09 |
| 10:32 ET | 556 | 2.088 |
| 10:33 ET | 1325 | 2.06 |
| 10:39 ET | 100 | 2.06 |
| 10:44 ET | 100 | 2.11 |
| 10:55 ET | 200 | 2.095 |
| 10:57 ET | 100 | 2.095 |
| 11:00 ET | 650 | 2.0975 |
| 11:09 ET | 334 | 2.095 |
| 11:13 ET | 300 | 2.0801 |
| 11:15 ET | 500 | 2.1 |
| 11:18 ET | 1800 | 2.149 |
| 11:20 ET | 100 | 2.15 |
| 11:24 ET | 3916 | 2.13 |
| 11:27 ET | 600 | 2.1 |
| 11:29 ET | 1507 | 2.08 |
| 11:31 ET | 249 | 2.1 |
| 11:45 ET | 100 | 2.12 |
| 11:58 ET | 2300 | 2.12 |
| 12:00 ET | 200 | 2.12 |
| 12:02 ET | 2600 | 2.13 |
| 12:09 ET | 200 | 2.13 |
| 12:12 ET | 999 | 2.11 |
| 12:14 ET | 300 | 2.12 |
| 12:16 ET | 100 | 2.12 |
| 12:20 ET | 10700 | 2.09 |
| 12:36 ET | 100 | 2.119 |
| 12:41 ET | 300 | 2.1055 |
| 12:54 ET | 529 | 2.119 |
| 12:56 ET | 100 | 2.105 |
| 01:08 ET | 1040 | 2.1 |
| 01:24 ET | 528 | 2.065 |
| 01:26 ET | 250 | 2.0547 |
| 01:37 ET | 520 | 2.025 |
| 01:39 ET | 568 | 2.023 |
| 01:48 ET | 1797 | 2.025 |
| 01:53 ET | 100 | 2.01 |
| 02:02 ET | 3370 | 2.0101 |
| 02:04 ET | 100 | 2.015 |
| 02:06 ET | 100 | 2.015 |
| 02:15 ET | 2811 | 2.01 |
| 02:24 ET | 724 | 2.015 |
| 02:26 ET | 400 | 2.01 |
| 02:45 ET | 400 | 2.015 |
| 03:23 ET | 440 | 2.0201 |
| 03:27 ET | 4677 | 2.025 |
| 03:36 ET | 200 | 2.04 |
| 03:39 ET | 100 | 2.03 |
| 03:41 ET | 200 | 2.02 |
| 03:43 ET | 121 | 2.02 |
| 03:56 ET | 300 | 2.025 |
| 03:57 ET | 400 | 2.04 |
| 03:59 ET | 959 | 2.03 |
May 10, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Immix Biopharma Inc | 54.9M | -2.2x | --- |
Carmell Corp | 55.1M | -1.6x | --- |
Mural Oncology PLC | 56.5M | -0.3x | --- |
Reneo Pharmaceuticals Inc | 56.8M | -0.8x | --- |
vTv Therapeutics Inc | 57.2M | -2.0x | --- |
OKYO Pharma Ltd | 45.0M | -0.1x | --- |
Company Information
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).
Contact Information
- Headquarters
- 11400 West Olympic Blvd., Suite 200LOS ANGELES, CA, United States 90064
- Phone
- 310-651-8041
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Ilya Rachman
- Scientific Co-Founder
- Vladimir Torchilin
- Chief Financial Officer, Director
- Gabriel Morris
- Head - Chemistry, Manufacturing, and Control
- Nandan Oza
- Acting Chief Medical Officer, Head - Clinical Development
- Graham Ross
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $54.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 26.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.93 |
Book Value | $0.82 |
P/E Ratio | -2.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
